Aflibercept clinical trials
Aflibercept is named as an intervention in 44 current clinical trials in our USA, Mexico, UK, Germany, Japan, Australia, China, France, Spain, Canada, Italy, Poland, Switzerland, Israel, Czechia, Brazil, Portugal, South Korea, Sweden, Austria, India, Netherlands, Denmark and Norway registers. 16 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Bayer (5). The most-studied condition is Diabetic Macular Edema. The EU clinical trials register (CTIS) separately lists 3 authorised or ongoing trials.
Where Aflibercept is approved
All regulators →Of the three regulators tracked here, the first to approve Aflibercept was the US, on 18 Nov 2011. It is approved in 3 of the 3 regulators tracked here.
- 6 FDA-approved biosimilars, 5 interchangeable: Ahzantive, Enzeevu, Eydenzelt, Opuviz and others
- 1 EU safety letter (DHPC), latest: adverse event for Eylea, 15 Apr 2021
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
What health systems spend on Aflibercept
All medicines →From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.
How Aflibercept works
All drug targets →- Vascular endothelial growth factor A inhibitor InhibitorTarget: VEGFA vascular endothelial growth factor AChEMBL only
- Placenta growth factor inhibitor InhibitorTarget: PGF placental growth factorChEMBL only
- Polypoidal choroidal vasculopathyPhase 3
- Progressive visual lossPhase 3
- Visual impairmentPhase 3
- Visual lossPhase 3
- Age-related macular degenerationPhase 3
- Diabetes mellitusPhase 3
- Malignant pancreatic neoplasmPhase 3
- Neovascular glaucomaPhase 3
- Non-proliferative diabetic retinopathyPhase 3
- Non-small cell lung carcinomaPhase 3
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL1742982, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 6786, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
NICE appraisals of Aflibercept
All NICE appraisals →NICE, which decides whether the NHS in England should fund new medicines, has published 6 technology appraisals of Aflibercept. 6 are current, and 5 of these recommend it for at least some patients.
| Appraisal | NICE recommendation | Published | Status |
|---|---|---|---|
| Aflibercept for treating choroidal neovascularisation NICE TA486 | Recommended | 1 Nov 2017 | Current |
| Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion NICE TA409 | Recommended | 28 Sep 2016 | Current |
| Aflibercept for treating diabetic macular oedema NICE TA346 | Optimised | 22 Jul 2015 | Current |
| Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy NICE TA307 | Not recommended | 25 Mar 2014 | Current |
| Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion NICE TA305 | Recommended | 26 Feb 2014 | Current |
| Aflibercept solution for injection for treating wet age‑related macular degeneration NICE TA294 | Recommended | 24 Jul 2013 | Current |
NICE decisions apply to the NHS in England. In Ireland the HSE decides on reimbursement, advised by the National Centre for Pharmacoeconomics. Titles, categories and dates link to the guidance on nice.org.uk. © NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.
Patient leaflets for Aflibercept
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- IEIreland: 21 products on the HPRA listEach product record links to the HPRA, which publishes the leaflet and SmPC.
- EU
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Reference identifiers for Aflibercept
- ChEMBL
- CHEMBL1742982
- DrugBank
- DB08885
- CAS number
- 845771-78-0
- Wikidata
- Q4689286
- Wikipedia
- Aflibercept
Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.
Trials by status
Trials by phase
Clinical trials of Aflibercept
44 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Aflibercept in the EU trials register (CTIS)
3 trialsAuthorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Aflibercept. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
Aflibercept across our data
Ireland · EU · USThe same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
Licensed in Ireland (HPRA)
21 single-substance products containing Aflibercept on the HPRA medicines list.
- Afiveg 40 mg/mL solution for injectionStada Arzneimittel AG · EU/1/25/1965/001
- Afiveg 40 mg/mL solution for injection in pre-filled syringeStada Arzneimittel AG · EU/1/25/1965/002
- AfqlirSandoz GmbH · EU/1/24/1867/001
- AfqlirSandoz GmbH · EU/1/24/1867/002
- Ahzantive 40 mg/ml Solution for injectionFormycon AG · EU/1/24/1888/001
Supply shortages
No entry for Aflibercept in the EMA, FDA or German BfArM shortage lists we track.
Conditions studied with Aflibercept
45 conditionsAll 45 conditions
| Condition (as registered) | Trials |
|---|---|
| Diabetic Macular Edema | 7 |
| Diabetic Macular Edema (DME) | 5 |
| Neovascular Age-Related Macular Degeneration (nAMD) | 5 |
| Wet Age-related Macular Degeneration | 3 |
| wAMD | 3 |
| Neovascular Age-related Macular Degeneration (nAMD) | 3 |
| Wet AMD | 3 |
| Neovascular Age-Related Macular Degeneration | 3 |
| Neovascular Age-related Macular Degeneration | 3 |
| Macular Degeneration | 2 |
| Age-Related Macular Degeneration | 2 |
| Choroidal Neovascularization | 2 |
| Wet Macular Degeneration | 2 |
| Diabetic Retinopathy | 2 |
| Macular Edema | 2 |
| Wet Age Related Macular Degeneration | 2 |
| Retinopathy of Prematurity | 2 |
| DME | 2 |
| Exudative Age-Related Macular Degeneration | 2 |
| AMD | 1 |
| nAMD | 1 |
| Preterm Infants | 1 |
| Visual Impairment | 1 |
| Diabetic Macula Edema (DME) | 1 |
| Neovascular (Wet) Age-related Macular Degeneration (AMD) | 1 |
| Age-related Wet Macular Degeneration | 1 |
| Neovascular Age-Related Macular Degeneration (NVAMD) | 1 |
| Branch Retinal Vein Occlusion (BRVO) | 1 |
| Diabetic Retinopathy (DR) | 1 |
| Center-Involved Diabetic Macular Edema (CI-DME) | 1 |
| Diabetic Retinopathy, DR | 1 |
| Wet Age-related Macular Degeneration (wAMD) | 1 |
| Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD | 1 |
| Neovascular (Wet) Age-Related Macular Degeneration | 1 |
| Age Related Macular Degeneration | 1 |
| Intravitreal Injections | 1 |
| Clinical Stage IV Cutaneous Melanoma AJCC v8 | 1 |
| Metastatic Colorectal Carcinoma | 1 |
| Metastatic Malignant Solid Neoplasm | 1 |
| Metastatic Melanoma | 1 |
| Newborns | 1 |
| Infants | 1 |
| Neovascular Glaucoma | 1 |
| Polypoidal Choroidal Vasculopathy | 1 |
| Polypoidal Choroidal Vasculopathy (PCV) | 1 |
Sponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Bayer | 5 |
| EyePoint Pharmaceuticals, Inc | 4 |
| AbbVie | 3 |
| EyeBiotech Ltd | 3 |
| Merck Sharp & Dohme LLC | 2 |
| Adverum Biotechnologies, Inc | 2 |
| Kodiak Sciences Inc | 2 |
| Ocular Therapeutix, Inc | 2 |
| Innostellar Biotherapeutics Co.,Ltd | 2 |
| Kyowa Kirin Co., Ltd | 1 |
| Exegenesis Bio | 1 |
| Alimera Sciences | 1 |
| Caregen Co. Ltd | 1 |
| Regeneron Pharmaceuticals | 1 |
| Alcon Research | 1 |
+ 13 more sponsors in the trial list above.
By country register
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
Related compounds
Questions about Aflibercept trials
How many clinical trials are testing Aflibercept?
44 current trials in our USA, Mexico, UK, Germany, Japan, Australia, China, France, Spain, Canada, Italy, Poland, Switzerland, Israel, Czechia, Brazil, Portugal, South Korea, Sweden, Austria, India, Netherlands, Denmark and Norway registers name Aflibercept (also registered as BAY86-5321) as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are Aflibercept trials recruiting patients?
Yes. 16 of the 44 trials are recruiting: 8 with sites in USA, 1 with sites in Mexico, 3 with sites in UK, 1 with sites in Germany, 1 with sites in Japan, 2 with sites in Australia, 3 with sites in China, 2 with sites in France, 2 with sites in Spain, 1 with sites in Italy, 1 with sites in Poland, 1 with sites in Switzerland, 1 with sites in Israel, 1 with sites in Czechia, 1 with sites in Brazil, 1 with sites in Portugal, 1 with sites in South Korea and 1 with sites in Austria. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Aflibercept clinical trials?
Bayer (5), EyePoint Pharmaceuticals, Inc (4), AbbVie (3) and EyeBiotech Ltd (3), among 28 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Is Aflibercept licensed in Ireland?
Yes. The HPRA medicines list includes 21 single-substance products containing Aflibercept, for example Afiveg 40 mg/mL solution for injection (Stada Arzneimittel AG). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Is there a Aflibercept shortage?
Not in the lists we track: Aflibercept has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Aflibercept works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Aflibercept works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Aflibercept (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.